PDF(Pubmed)
Abstract：
Adequate diet, physical activity, and dietary supplementation with muscle-targeted food for special medical purposes (FSMP) or dietary supplement (DS) are currently considered fundamental pillars in sarcopenia treatment. The aim of this study is to evaluate the effectiveness of a DS (containing hydroxy-methyl-butyrate, carnosine, and magnesium, for its action on muscle function and protein synthesis and butyrate and lactoferrin for their contribution to the regulation of gut permeability and antioxidant/anti-inflammation activity) on muscle mass (assessed by dual X-ray absorptiometry (DXA)), muscle function (by handgrip test, chair test, short physical performance battery (SPPB) test, and walking speed test), inflammation (tumor necrosis factor-alpha (TNF-a), C-reactive protein (CRP), and visceral adipose tissue (VAT)) and gut axis (by zonulin). A total of 59 participants (age 79.7 ± 4.8 years, body mass index 20.99 ± 2.12 kg/m2) were enrolled and randomly assigned to intervention (n = 30) or placebo (n = 28). The skeletal muscle index (SMI) significantly improved in the supplemented group compared to the placebo one, +1.02 (CI 95%: -0.77; 1.26), p = 0.001; a significant reduction in VAT was observed in the intervention group, -70.91 g (-13.13; -4.70), p = 0.036. Regarding muscle function, all the tests significantly improved (p = 0.001) in the supplemented group compared to the placebo one. CRP, zonulin, and TNF-alpha significantly decreased (p = 0.001) in intervention, compared to placebo, -0.74 mg/dL (CI 95%: -1.30; -0.18), -0.30 ng/mL (CI 95%: -0.37; -0.23), -6.45 pg/mL (CI 95%: -8.71; -4.18), respectively. This DS improves muscle mass and function, and the gut muscle has emerged as a new intervention target for sarcopenia.
摘要：
充足的饮食，身体活动,以及用于特殊医疗目的的肌肉靶向食物（FSMP）或膳食补充剂（DS）的膳食补充剂目前被认为是肌肉减少症治疗的基本支柱。本研究的目的是评估DS（含羟甲基丁酸酯，肌肽,还有镁,由于其对肌肉功能和蛋白质合成的作用，以及丁酸盐和乳铁蛋白对肠道通透性和抗氧化/抗炎活性的调节的贡献）对肌肉质量（通过双重X射线吸收法（DXA）评估），肌肉功能(通过握力测试，椅子测试,短物理性能电池（SPPB）测试，和步行速度测试)，炎症（肿瘤坏死因子-α（TNF-a），C反应蛋白(CRP),和内脏脂肪组织（VAT））和肠轴（通过zonulin）。共有59名参与者（年龄79.7±4.8岁，纳入体重指数20.99±2.12kg/m2),并随机分配至干预组(n=30)或安慰剂组(n=28).与安慰剂组相比，补充组的骨骼肌指数（SMI）显着提高，+1.02（CI95%：-0.77；1.26），p=0.001；干预组中观察到增值税的显着降低，-70.91g(-13.13;-4.70),p=0.036。关于肌肉功能，与安慰剂组相比，补充组的所有测试均显着改善（p=0.001）。CRP,zonulin,和TNF-α在干预中显着降低（p=0.001），与安慰剂相比，-0.74mg/dL（CI95%：-1.30；-0.18），-0.30ng/mL（CI95%：-0.37；-0.23），-6.45pg/mL（CI95%：-8.71；-4.18），分别。这种DS改善肌肉质量和功能，肠道肌肉已成为肌肉减少症的新干预目标。
